Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 320-326

  Vokes, Everett E ^a   Stenson, Kerstin ^a   Rosen, Fred R ^a   Kies, Merrill S ^a   Rademaker, Alfred W ^a   Witt, Mary Ellyn ^a   Brockstein, Bruce E ^a   List, Marcy A ^a   Fung, Bing Bing ^a   Portugal, Louis ^a   Mittal, Bharat B ^a   Pelzer, Harold ^a   Weichselbaum, Ralph R ^a   Haraf, Daniel J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; FLUOROURACIL; HYDROXYUREA; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DERMATITIS; FEEDING APPARATUS; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORGAN PRESERVATION; PRIORITY JOURNAL; SORE THROAT; TREATMENT FAILURE; TREATMENT RESPONSE; ADULT; AGED; DISEASE COURSE; FEMALE; HEAD AND NECK TUMOR; LYMPH NODE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; QUALITY OF LIFE; RADIATION DOSE; REMISSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; LYMPH NODES; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037440070     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.006     Document Type: Article

References (46)

1. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
2. Lamont E, Vokes EE: Chemotherapy in the management of squamous cell carcinoma of the head and neck. Lancet Oncol 2:261-269, 2001
3. El-Sayed S, Nelson N: Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838-847, 1996
4. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to loco-regional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
5. Wendt T, Grabenbauer G, Rodel C, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998
6. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
7. Jeremic B, Shibamoto Y, Milicic B, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 18:1458-1464, 2000
8. Calais G, Alfonsi M, Bardet E, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999
9. Forastiere A, Berkey B, Maor M, et al: Phase III trial to preserve the larynx: Induction chemotherapy and radiotherapy versus concomitant chemoradiotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 4)
10. Yokes EE, Athanasiadis I: Chemotherapy of squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7:15-29, 1996
11. Adelstein D: Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 13:689-698, v-vi, 1999
12. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
13. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996
14. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
15. Vokes EE, Kies M, Haraf DJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. J Clin Oncol 13:876-883, 1995
16. Kies M, Haraf D, Athanasiadis I, et al: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: Improved disease control and survival. J Clin Oncol 16:2715-2721, 1998
17. Vokes E, Kies M, Haraf D, et al: Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18:1652-1661, 2000
18. Kies MS, Haraf DJ, Rosen F, et al: Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19:1961-1969, 2001
19. Rosen FR, Haraf D, Brockstein B, et al: Multicenter randomized phase II study of 1 hour (H) infusion paclitaxel (T), fluorouracil (F) and hydroxyurea (H) with concomitant hyperfractionated radiotherapy (2XRT) with or without erythropoietin (EP) for advanced head and neck cancer (HNC). Proc Am Soc Clin Oncol 20:226a, 2001 (abstr 902)
20. Adelstein DJ, Saxton JP, Lavertu P, et al: Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20:1405-1410, 2002
21. Kumar P, Robbins KT: Treatment of advanced head and neck cancer with intra-arterial cisplatin and concurrent radiation therapy: The "RAD-PLAT" protocol. Curr Oncol Rep 3:59-65, 2001
22. Murphy B, Li Y, Cella D, et al: Phase III study comparing cisplatin (C) & 5-flurouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck cancer (MHNC). Proc Am Soc Clin Oncol 20:224a, 2001 (abstr 894)
23. Forastiere AA, Shank D, Neuberg D, et al: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270-2274, 1998
24. Akerley W, Rathore R, Ready N, et al: A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer 95:2000-2005, 2002
25. Belani CP: Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol 28:14-16, 2001
26. Pajak TF, Laramore GE, Marcial VA, et al: Elapsed treatment days-A critical item for radiotherapy quality control review in head and neck trials: RTOG report. Int J Radiat Oncol Biol Phys 20:13-20, 1991
27. Ang KK: Altered fractionation trials in head and neck cancer. Semin Radiat Oncol 8:230-236, 1998
28. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
29. Brockstein B, Haraf DJ, Stenson K, et al: Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol 16:735-744, 1998
30. Brockstein B, Haraf DJ, Stenson K, et al: A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol 11:721-728, 2000
31. List MA, Siston A, Haraf D, et al: Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination. J Clin Oncol 17:1020-1028, 1999
32. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
33. Cella D: Manual for the functional assessment of chronic illness therapy (FACIT) scales. Center on Outcomes Research and Education, Evanston Northwestern Healthcare, Evanston, IL, 1997
34. List MA, Ritter-Sterr C, Lansky SB: A performance status scale for head and neck cancer patients. Cancer 66:564-569, 1990
35. List MA, D'Antonio LL, Cella DF, et al: The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale. A study of utility and validity. Cancer 77:2294-2301, 1996
36. Browman GP, Levine MN, Hodson DI, et al: The Head and Neck Radiotherapy Questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 11:863-872, 1993
37. Radloff L: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Measure 3:385-401, 1977
38. Rosner B: Fundamentals of Biostatistics (ed 5). Pacific Grove, CA, Duxbury Press, 2000
39. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
40. Colevas AD, Norris CM, Tishler RB, et al: Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 17:3503-3511, 1999
41. Stenson KM, Haraf DJ, Pelzer H, et al: The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: The feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 126:950-956, 2000
42. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
43. Adelstein DJ, Adams GL, Ki Y, et al: A phase III comparison of starndard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): An Intergroup study. Proc Am Soc Clin Oncol 19:411a, 2000 (abstr 1624)
44. Senzer N, Soulieres D, Siu L, et al: Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 20:2a, 2001 (abstr 6)
45. Cohen E, Rosen F, Dekker A, et al: Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 21:225a, 2002
46. Hong W, Arquette M, Nabell L, et al: Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 20:224a, 2001 (abstr 895)